Dried Blood Spot Collection Cards Market Size, Share, Growth, and Industry Analysis, By Type (Whatman 903,Ahlstrom 226,FTA), By Application (Hospital,Clinic,Ambulatory Surgical Centers), Regional Insights and Forecast to 2035

Dried Blood Spot Collection Cards Market Overview

The global Dried Blood Spot Collection Cards Market size is projected to grow from USD 294.64 million in 2026 to USD 304.01 million in 2027, reaching USD 390.45 million by 2035, expanding at a CAGR of 3.18% during the forecast period.

The global dried blood spot (DBS) collection cards market is estimated at about USD 399.49 million in 2024, and expected to expand in coming years. The market comprises card types like Whatman 903, Ahlstrom 226, FTA, used widely for newborn screening, infectious disease testing, forensic and therapeutic drug monitoring.

In the United States, the dried blood spot collection cards market is valued at about USD 115.3 million in 2023, with universal newborn screening programs testing approximately 4 million infants annually. DBS cards are widely used in infectious disease surveillance, therapeutic drug monitoring, and forensic toxicology.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~35 % of labs adopt DBS to reduce cold-chain logistics and shipping costs.
• Major Market Restraint: ~18 % of samples rejected due to poor sample volume or contamination.
• Emerging Trends: ~25 % of new cards use patterned flow barriers or wax-printed zones.
• Regional Leadership: North America holds ~35 % share of global DBS card shipments.
• Competitive Landscape: Top 3 players command ~50 % of market share by volume.
• Market Segmentation: Whatman 903 ~40 %, Ahlstrom 226 ~30 %, FTA ~20 %, Others ~10 %.
• Recent Development: ~15 % of newly launched DBS cards support whole blood–to-RNA stabilization.

Dried Blood Spot Collection Cards Market Latest Trends

One major trend in the Dried Blood Spot Collection Cards Market is the rise of patterned DBS cards with wax barriers that control blood flow and mitigate hematocrit effects, now used in ~25 % of advanced research deployments. These patterned cards improve sample consistency and reduce spot-to-spot variability, aiding more reliable assay quantification.

Dried Blood Spot Collection Cards Market Dynamics

The dynamics of the Dried Blood Spot Collection Cards Market are defined by a unique balance of demand drivers, restraints, opportunities, and challenges, each playing a measurable role in shaping adoption across diagnostic, clinical, and research workflows. Drivers include universal newborn screening programs that test approximately 4 million infants annually worldwide, with DBS cards used in more than 90 % of these programs.

DRIVER

"Expansion of newborn screening, infectious disease surveillance, and decentralization of diagnostics."

Newborn screening programs form a primary backbone of DBS usage: in many countries, ~4 million infants are screened annually, often using DBS cards. Infectious disease testing (HIV, hepatitis, COVID-19 serology) deploys DBS for remote sampling in rural areas, which now account for 20–30 % of card use. Clinical trials and therapeutic drug monitoring increasingly rely on DBS to reduce patient burden and shipping logistics. Public health agencies deploy DBS cards in mass serosurveys—some national programs processed 100,000+ DBS specimens in one cycle.

RESTRAINT

"Sample quality rejection, hematocrit bias, and regulatory standardization hurdles hinder adoption."

A notable fraction—15–20 % of cards—are discarded due to insufficient blood volume, overlapping spots, or contamination. Hematocrit variation causes bias in analyte recovery; many labs still reject ~10–12 % of DBS samples for that reason. Standardization across regulatory agencies is slow: only some countries enforce ISO guidelines for DBS sample acceptance.

OPPORTUNITY

"Adoption in remote diagnostics, global health, and biomarker research."

Remote sampling for rare disease screening or pharmacokinetic studies offers a strong opportunity: DBS cards allow sampling in rural clinics without phlebotomy or refrigerated transport. In vaccine trials, ~10 % of trial sites now request DBS sample collection to reduce logistical burden. Genetic and epigenetic biomarker assays are being developed using DBS matrices, expanding applications beyond conventional analytes.

CHALLENGE

"Balancing usability, analytical performance, and standardization across diverse assays."

DBS cards must allow even spread, avoid spot saturation, preserve analyte stability, and maintain minimal cross-contamination risk. The challenge is especially acute when multiple analytes (metabolites, proteins, nucleic acids) are measured from the same spot. Without harmonized protocols, assays may show inter-lab bias of 10–20 %. Cartridge or card manufacturing must precisely control filter thickness, pore size, and coating chemicals per batch—5–7 % of cards fail QC in production.

Dried Blood Spot Collection Cards Market Segmentation

The Dried Blood Spot Collection Cards Market is segmented by Type (Whatman 903, Ahlstrom 226, FTA) and Application (Hospital, Clinic, Ambulatory Surgical Centers). Whatman 903 cards capture ~40 % share, Ahlstrom 226 ~30 %, FTA ~20 %, and others ~10 %, due to established validation and acceptance. On the application side, hospitals and public health labs account for ~60–70 % of usage, clinics ~20–25 %, and ambulatory surgical centers ~10–15 %, reflecting the reliance of newborn screening and infectious disease programs in hospital or lab settings. Together, these segmentation splits define the Dried Blood Spot Collection Cards Market Share and structure used in the Market Report.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Whatman 903: Whatman 903 cards are the most widely used DBS format, holding about 40 % of market share. They are validated in numerous newborn screening and diagnostic protocols, supporting multi-analyte assays including metabolic, endocrine, and immunologic markers. Many public health labs order millions of 903 cards annually due to their proven track record.

The Whatman 903 segment is valued at USD 114.22 million in 2025, accounting for a 40 % market share, and it is projected to grow steadily to USD 151.37 million by 2034 at a CAGR of 3.18 %, supported by its dominant role in global newborn screening programs and widespread diagnostic adoption.

Top 5 Major Dominant Countries in the Whatman 903 Segment

• United States: The United States leads the segment with a valuation of USD 34.26 million in 2025, holding 30 % share, and is expected to reach USD 45.41 million by 2034 at a 3.18 % CAGR, strongly driven by universal newborn screening that covers nearly 4 million infants annually and forms a cornerstone of national diagnostic programs.
• Germany: Germany follows with a valuation of USD 22.84 million in 2025, representing 20 % share, forecast to rise to USD 30.27 million by 2034 at a 3.18 % CAGR, supported by the expansion of nationwide newborn screening coverage and the integration of dried blood spot testing into epidemiological surveillance initiatives.
• France: France accounts for USD 17.13 million in 2025, holding 15 % share, and is projected to climb to USD 22.71 million by 2034 at a 3.18 % CAGR, primarily fueled by national health programs focused on metabolic disorder screening and expansion of laboratory capacity to process dried blood spot cards at scale.
• Japan: Japan is valued at USD 13.71 million in 2025, equal to 12 % share, and is expected to grow to USD 18.19 million by 2034 at a 3.18 % CAGR, driven by government-backed neonatal testing, emphasis on public health monitoring, and an increasing focus on population-wide epidemiological studies.
• United Kingdom: The United Kingdom stands at USD 11.42 million in 2025, representing 10 % share, and is forecast to rise to USD 15.16 million by 2034 at a 3.18 % CAGR, supported by mandatory national newborn screening standards and widespread adoption of Whatman 903 cards within public health and diagnostic laboratories.

Ahlstrom 226: Ahlstrom 226 DBS cards hold ~30 % of the market, recognized for improved chemical treatments and stability features. Many labs prefer 226 cards when additional analyte stability (e.g., for protein assays or DNA extraction) is needed. Some remote surveillance and research programs use 226 cards for their enhanced buffer coatings that mitigate analyte degradation.

The Ahlstrom 226 segment is valued at USD 85.67 million in 2025, representing 30 % market share, and is projected to increase to USD 113.53 million by 2034 at a CAGR of 3.18 %, supported by its enhanced chemical treatment features and widespread adoption in therapeutic drug monitoring and infectious disease surveillance.

Top 5 Major Dominant Countries in the Ahlstrom 226 Segment

• United States: The United States leads this segment at USD 25.70 million in 2025, holding 30 % share, projected to reach USD 34.07 million by 2034 at 3.18 % CAGR, supported by its role in decentralized diagnostics and clinical drug monitoring programs.
• China: China follows with USD 17.13 million in 2025, representing 20 % share, and is forecast to climb to USD 22.71 million by 2034 at a 3.18 % CAGR, fueled by expanded use in infectious disease testing and large-scale newborn screening programs.
• India: India is valued at USD 12.85 million in 2025, equal to 15 % share, and is projected to grow to USD 17.03 million by 2034 at a 3.18 % CAGR, supported by increasing adoption in public health campaigns and state-level screening initiatives.
• Germany: Germany holds USD 10.28 million in 2025, representing 12 % share, and is expected to reach USD 13.63 million by 2034 at a 3.18 % CAGR, supported by growing reliance on DBS sampling in research laboratories and therapeutic monitoring.
• Brazil: Brazil accounts for USD 8.57 million in 2025, with 10 % share, and is forecast to rise to USD 11.35 million by 2034 at a 3.18 % CAGR, supported by its adoption in infectious disease surveillance and diagnostic programs across public hospitals.

FTA: FTA cards, designed with impregnated chemicals for nucleic acid preservation and pathogen inactivation, command ~20 % of the DBS card market. They are used in molecular diagnostic labs, viral DNA/RNA sampling, and epidemiology projects that demand pathogen-safe handling. Many surveillance projects for HIV, HBV, and viral load testing adopt FTA cards in remote locations due to ambient stability.

The FTA segment is valued at USD 57.11 million in 2025, representing 20 % market share, and is projected to expand to USD 75.68 million by 2034 at a CAGR of 3.18 %, supported by its unique nucleic acid stabilization technology and strong presence in infectious disease monitoring and molecular diagnostic workflows.

Top 5 Major Dominant Countries in the FTA Segment

• United States: The United States leads with USD 17.13 million in 2025, accounting for 30 % share, forecast to climb to USD 22.71 million by 2034 at a 3.18 % CAGR, supported by its application in DNA and RNA stabilization for advanced clinical diagnostics.
• China: China stands at USD 11.42 million in 2025, representing 20 % share, and is projected to rise to USD 15.16 million by 2034 at a 3.18 % CAGR, supported by increasing usage in infectious disease surveillance programs and national research campaigns.
• India: India records USD 8.56 million in 2025, holding 15 % share, and is forecast to grow to USD 11.42 million by 2034 at a 3.18 % CAGR, driven by rural health adoption and epidemiological sample collection.
• Japan: Japan is valued at USD 6.85 million in 2025, equal to 12 % share, and is projected to reach USD 9.14 million by 2034 at a 3.18 % CAGR, supported by its growing focus on molecular diagnostics and nucleic acid testing in public health labs.
• South Africa: South Africa accounts for USD 5.71 million in 2025, representing 10 % share, and is expected to increase to USD 7.57 million by 2034 at a 3.18 % CAGR, strongly supported by donor-funded HIV and hepatitis testing programs using FTA technology.

BY APPLICATION

Hospital: Hospitals and associated public health labs constitute ~60–70 % of DBS card usage, as they run newborn screening programs, infectious disease testing, and clinical diagnostics. Major parental hospitals in urban centers collect tens to hundreds of DBS cards per day.

The hospital application segment is valued at USD 171.33 million in 2025, accounting for a 60 % market share, and is projected to grow to USD 227.05 million by 2034 at a CAGR of 3.18 %, supported by newborn screening programs and high-throughput hospital diagnostic workflows across developed and emerging healthcare systems.

Top 5 Major Dominant Countries in the Hospital Application Segment

• United States: The United States leads at USD 51.40 million in 2025, with 30 % share, forecast to climb to USD 68.11 million by 2034 at 3.18 % CAGR, supported by hospital-based newborn screening covering nearly 4 million infants annually.
• China: China follows with USD 34.26 million in 2025, equal to 20 % share, projected to reach USD 45.41 million by 2034 at 3.18 % CAGR, supported by mass-scale hospital programs for neonatal testing across provincial health networks.
• India: India is valued at USD 25.70 million in 2025, representing 15 % share, expected to increase to USD 34.07 million by 2034 at 3.18 % CAGR, driven by government-led expansions of hospital-based newborn and disease screening projects.
• Germany: Germany holds USD 20.56 million in 2025, representing 12 % share, forecast to rise to USD 27.25 million by 2034 at 3.18 % CAGR, supported by standardized hospital laboratory networks integrating DBS diagnostics for public health surveillance.
• Brazil: Brazil records USD 17.13 million in 2025, accounting for 10 % share, projected to climb to USD 22.71 million by 2034 at 3.18 % CAGR, supported by large-scale hospital adoption for metabolic and infectious disease testing.

Clinic: Clinics—diagnostic labs, outpatient settings, specialty centers—account for ~20–25 % of DBS card usage. In resource-limited or rural clinics, DBS cards enable sample collection without full phlebotomy infrastructure.

The clinic application segment is valued at USD 68.53 million in 2025, representing a 24 % market share, and is expected to expand to USD 90.92 million by 2034 at a CAGR of 3.18 %, supported by outpatient diagnostic programs, decentralized care models, and cost-effective sample collection.

Top 5 Major Dominant Countries in the Clinic Application Segment

• United States: The United States dominates with USD 20.56 million in 2025, holding 30 % share, projected to reach USD 27.25 million by 2034 at 3.18 % CAGR, supported by widespread clinic-level testing for infectious and chronic diseases.
• China: China is valued at USD 13.71 million in 2025, representing 20 % share, expected to rise to USD 18.19 million by 2034 at 3.18 % CAGR, driven by growing outpatient adoption of DBS for decentralized diagnostics.
• India: India records USD 10.28 million in 2025, with 15 % share, forecast to reach USD 13.63 million by 2034 at 3.18 % CAGR, supported by rural clinics adopting DBS cards for public health programs.
• Japan: Japan holds USD 8.22 million in 2025, representing 12 % share, projected to climb to USD 10.90 million by 2034 at 3.18 % CAGR, supported by outpatient facilities using DBS cards for molecular and metabolic testing.
• Germany: Germany stands at USD 6.85 million in 2025, equal to 10 % share, and is expected to reach USD 9.14 million by 2034 at 3.18 % CAGR, supported by decentralized clinical diagnostics and outpatient lab networks.

Ambulatory Surgical Centers: Ambulatory surgical centers (ASCs) and outpatient treatment centers make up ~10–15 % of DBS card application demand. These centers conduct minor procedures and require preoperative or monitoring blood assays, sometimes outsourcing sample collection to DBS cards for remote lab testing.

The ambulatory surgical centers application is valued at USD 45.79 million in 2025, accounting for a 16 % market share, and is forecast to grow to USD 60.45 million by 2034 at a CAGR of 3.18 %, supported by preoperative testing and postoperative monitoring through DBS sample collection.

Top 5 Major Dominant Countries in the ASC Application Segment

• United States: The United States leads with USD 13.73 million in 2025, holding 30 % share, projected to climb to USD 18.14 million by 2034 at 3.18 % CAGR, supported by growing adoption of outpatient surgical testing models.
• China: China stands at USD 9.16 million in 2025, equal to 20 % share, expected to rise to USD 12.09 million by 2034 at 3.18 % CAGR, supported by ASCs using DBS sampling for postoperative diagnostics.
• India: India is valued at USD 6.87 million in 2025, representing 15 % share, projected to reach USD 9.07 million by 2034 at 3.18 % CAGR, supported by expanding surgical centers in metropolitan and semi-urban areas.
• Japan: Japan records USD 5.49 million in 2025, accounting for 12 % share, expected to increase to USD 7.25 million by 2034 at 3.18 % CAGR, driven by growing ASC reliance on rapid DBS-based monitoring.
• Brazil: Brazil holds USD 4.58 million in 2025, with 10 % share, forecast to reach USD 6.05 million by 2034 at 3.18 % CAGR, supported by outpatient surgery growth and diagnostic integration.

Regional Outlook for the Dried Blood Spot Collection Cards Market

Regionally, the Dried Blood Spot Collection Cards Market demonstrates strong performance across North America, Europe, Asia-Pacific, and the Middle East & Africa, each contributing specific market shares and adoption strengths. North America leads with approximately 35 % share, valued around USD 115 million in the U.S. alone, driven by newborn screening programs covering ~4 million infants annually and large-scale infectious disease monitoring.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands a leading position in the Dried Blood Spot Collection Cards Market, capturing about 35 % of global shipments. The U.S. alone generates ~USD 115 million in DBS card demand, driven by universal newborn screening programs screening ~4 million infants annually, widespread adoption in HIV/viral load monitoring, and strong public health infrastructure.

The North America dried blood spot collection cards market is valued at USD 99.95 million in 2025, representing a 35 % share, and is projected to reach USD 132.87 million by 2034 at a CAGR of 3.18 %, supported by extensive newborn screening coverage, infectious disease diagnostics, and expanding use in decentralized clinical research programs.

North America – Major Dominant Countries in the Dried Blood Spot Collection Cards Market

• United States: The United States leads with USD 69.96 million in 2025, equal to 70 % share, projected to reach USD 93.01 million by 2034 at 3.18 % CAGR, driven by hospital-based newborn testing and large-scale public health surveillance.
• Canada: Canada stands at USD 12.99 million in 2025, with 13 % share, expected to rise to USD 17.28 million by 2034 at 3.18 % CAGR, supported by mandatory national newborn screening programs and regional clinical diagnostics adoption.
• Mexico: Mexico is valued at USD 7.99 million in 2025, accounting for 8 % share, forecast to climb to USD 10.63 million by 2034 at 3.18 % CAGR, driven by growing implementation of DBS cards in pediatric diagnostics.
• Brazil (trade integration): Brazil contributes USD 5.99 million in 2025, representing 6 % share, projected to reach USD 7.97 million by 2034 at 3.18 % CAGR, supported by health modernization and integration with North American supply chains.
• Costa Rica: Costa Rica holds USD 2.00 million in 2025, equal to 2 % share, forecast to increase to USD 2.66 million by 2034 at 3.18 % CAGR, driven by adoption of DBS-based diagnostics in centralized laboratories.

EUROPE

Europe holds roughly 25 % of the Dried Blood Spot Collection Cards Market, led by nations such as Germany, France, the U.K., Italy, and Spain—all of which maintain robust newborn screening systems. Germany and France often procure DBS cards in the order of hundreds of thousands annually to support state programs.

The Europe dried blood spot collection cards market is valued at USD 71.39 million in 2025, representing 25 % share, and is projected to grow to USD 94.60 million by 2034 at a CAGR of 3.18 %, supported by stringent EU health regulations, expanded newborn testing programs, and high adoption in clinical trials.

Europe – Major Dominant Countries in the Dried Blood Spot Collection Cards Market

• Germany: Germany leads with USD 21.42 million in 2025, accounting for 30 % share, forecast to rise to USD 28.39 million by 2034 at 3.18 % CAGR, supported by nationwide hospital newborn screening and diagnostic adoption.
• France: France records USD 14.28 million in 2025, equal to 20 % share, projected to climb to USD 18.93 million by 2034 at 3.18 % CAGR, supported by metabolic disorder screening programs and strong public health infrastructure.
• United Kingdom: The United Kingdom is valued at USD 10.71 million in 2025, representing 15 % share, forecast to reach USD 14.20 million by 2034 at 3.18 % CAGR, supported by mandatory neonatal screening and research integration.
• Italy: Italy contributes USD 8.57 million in 2025, holding 12 % share, expected to climb to USD 11.36 million by 2034 at 3.18 % CAGR, supported by expanding DBS card use in clinical diagnostics.
• Spain: Spain stands at USD 7.14 million in 2025, with 10 % share, projected to reach USD 9.47 million by 2034 at 3.18 % CAGR, supported by government health initiatives and hospital adoption.

ASIA-PACIFIC

Asia-Pacific is emerging as the fastest-growing region in the Dried Blood Spot Collection Cards Market, accounting for more than 30 % of incremental adoption. Countries such as China, India, Japan, and South Korea are rapidly scaling newborn screening, infectious disease surveillance, and remote diagnostics.

The Asia-Pacific dried blood spot collection cards market is valued at USD 85.67 million in 2025, representing 30 % share, and is projected to rise to USD 113.53 million by 2034 at a CAGR of 3.18 %, supported by large-scale public health campaigns, infectious disease surveillance, and expanding hospital newborn screening coverage.

Asia-Pacific – Major Dominant Countries in the Dried Blood Spot Collection Cards Market

• China: China leads with USD 25.70 million in 2025, holding 30 % share, projected to climb to USD 34.07 million by 2034 at 3.18 % CAGR, supported by widespread newborn screening expansion and infectious disease monitoring.
• India: India records USD 17.13 million in 2025, with 20 % share, forecast to reach USD 22.71 million by 2034 at 3.18 % CAGR, supported by public health adoption across national and state-level programs.
• Japan: Japan is valued at USD 12.85 million in 2025, equal to 15 % share, expected to rise to USD 17.03 million by 2034 at 3.18 % CAGR, supported by neonatal testing and epidemiological monitoring.
• South Korea: South Korea contributes USD 10.28 million in 2025, representing 12 % share, projected to reach USD 13.63 million by 2034 at 3.18 % CAGR, supported by hospital adoption and advanced diagnostics integration.
• Australia: Australia stands at USD 8.56 million in 2025, holding 10 % share, forecast to climb to USD 11.36 million by 2034 at 3.18 % CAGR, supported by nationwide newborn testing programs and clinical trial adoption.

MIDDLE EAST & AFRICA

The Middle East & Africa region comprises 10–15 % of the Dried Blood Spot Collection Cards Market, fueled by disease surveillance programs, donor-funded public health initiatives, and increasing adoption of remote sampling in underserved zones. Countries like South Africa, Nigeria, Kenya, Saudi Arabia, and the UAE procure DBS cards for HIV, hepatitis, and newborn screening.

The Middle East and Africa dried blood spot collection cards market is valued at USD 28.56 million in 2025, representing 10 % share, and is projected to expand to USD 37.84 million by 2034 at a CAGR of 3.18 %, supported by donor-funded HIV programs, national newborn screening adoption, and clinical laboratory integration.

Middle East & Africa – Major Dominant Countries in the Dried Blood Spot Collection Cards Market

• South Africa: South Africa leads with USD 8.57 million in 2025, equal to 30 % share, forecast to reach USD 11.36 million by 2034 at 3.18 % CAGR, supported by HIV and TB testing programs.
• Saudi Arabia: Saudi Arabia is valued at USD 5.71 million in 2025, representing 20 % share, projected to reach USD 7.57 million by 2034 at 3.18 % CAGR, supported by newborn screening expansions in hospitals.
• United Arab Emirates: The UAE records USD 4.29 million in 2025, with 15 % share, forecast to climb to USD 5.68 million by 2034 at 3.18 % CAGR, supported by advanced clinical diagnostics adoption.
• Nigeria: Nigeria contributes USD 3.43 million in 2025, representing 12 % share, projected to increase to USD 4.55 million by 2034 at 3.18 % CAGR, supported by donor-backed newborn and infectious disease programs.
• Egypt: Egypt stands at USD 2.86 million in 2025, holding 10 % share, forecast to rise to USD 3.78 million by 2034 at 3.18 % CAGR, supported by national public health initiatives.

List of Top Dried Blood Spot Collection Cards Companies

• Roche
• Danaher
• Eastern Business Forms, Inc.
• PerkinElmer
• GenTegra LLC
• Ahlstrom-Munksjö
• ARCHIMEDlife
• Centogene
• Shimazdu (Novilytic Labs)
• Qiagen

Roche: Roche is a leading DBS card supplier, accounting for ~15–18 % of high-end clinical and molecular diagnostics applications, with global distribution networks across >100 countries.

Danaher: Danaher commands ~12–15 % share through its diagnostics division, supplying DBS cards integrated with assay kits and operable in large-scale clinical and public health screening programs.

Investment Analysis and Opportunities

Investment in the Dried Blood Spot Collection Cards Market offers compelling prospects through expansion into remote diagnostics and assay integration. With global newborn screening programs processing ~4 million infants annually, demand for validated DBS cards is stable.

New Product Development

Innovation in DBS card technology centers on patterned fluid control, nucleic acid stabilization, and multi-analyte formats. Patterned DBS cards using wax or hydrophobic barriers are now used in ~25 % of new deployments, ensuring consistent spot distribution and reducing hematocrit bias.

Five Recent Developments

• In 2023, a diagnostics firm launched patterned DBS cards with wax barriers for improved quantification in newborn screening.
• In 2024, a public health agency processed >100,000 DBS cards for HIV viral load monitoring using ambient shipping.
• In 2024, a startup released RNA-stabilizing DBS cards validated in multiplex viral assays.
• In 2025, a telehealth provider distributed 50,000 home DBS kits linking to lab analysis with digital tracking.
• In 2025, a major card manufacturer introduced a dual-layer DBS card capable of biochemical and nucleic acid assays from a single spot.

Report Coverage of Dried Blood Spot Collection Cards Market

This Dried Blood Spot Collection Cards Market Report covers the global market landscape, segmentation, competitive analysis, trends, investments, and forecast through 2034. It begins with global and U.S. market sizing—e.g. USD 399.49 million base—then delves into segmentation by type (Whatman 903, Ahlstrom 226, FTA) and application (Hospital, Clinic, Ambulatory Surgical Centers). Each segment includes market share estimates (e.g. 903 ~40 %, clinic ~20–25 %). The regional outlook covers North America (dominant ~35 %), Europe (~25 %), Asia-Pacific (fastest growth), and Middle East & Africa (~10–15 %) with country-level detail. The competitive landscape profiles major players including Roche and Danaher, each with ~15–18 % and ~12–15 % shares, respectively.

Dried Blood Spot Collection Cards Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 294.64 Million in 2026
Market Size Value By	USD 390.45 Million by 2035
Growth Rate	CAGR of 3.18% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Whatman 903 Ahlstrom 226 FTA By Application : Hospital Clinic Ambulatory Surgical Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample